Tapewire

Nasdaq · USD

ORMP

ORAMED PHARMACEUTICALS INC.

Export transactions ↓
Tapewire entity
6311
SEC CIK
0001176309
Parsed reports
201

Last 12 months

Inside the activity.

0 purchase rows · 4 sale rows

Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.
Monthly counts
MonthPurchasesSales
Nov 202500
Dec 202500
Jan 202600
Feb 202600
Mar 202600
Apr 202600
May 202600
Jun 202600
Jul 202602
Aug 202600
Sep 202600
Oct 202602

Latest available

Insider transactions

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateOwner / reported roleActivity / securityShares / unitsReported priceReported valueDetails
October 01, 2026 Filed Oct 2, 2026 21:19 UTC
Hexter JoshuaCOO & CBO
SaleCommon Stock 30,000 $4.51 $135,330.00
Disclosure

SEC source: 0001213900-26-106530 · ownership.xml · nonDerivative · entry 1

Hexter Joshua · CIK 0001573235 · COO & CBO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,328,130

F1 · shares: Represents shares sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 30, 2026.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.440 to $4.650, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Read SEC document
October 01, 2026 Filed Oct 2, 2026 21:19 UTC
Gabay AvrahamChief Financial Officer
SaleCommon Stock 20,000 $4.51 $90,200.00
Disclosure

SEC source: 0001213900-26-106531 · ownership.xml · nonDerivative · entry 1

Gabay Avraham · CIK 0001777328 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 861,076

F1 · shares: Represents shares sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 30, 2026.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.440 to $4.650, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Read SEC document
September 24, 2026 Filed Sep 25, 2026 20:31 UTC
KIDRON NADAVDirector · President and CEO
Disposition to issuerStock option (right to buy) · Derivative 107,000 Not disclosed Strike: $13.89 Not disclosed
Disclosure

SEC source: 0001213900-26-103540 · ownership.xml · derivative · entry 9

KIDRON NADAV · CIK 0001351779 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 107,000 shares

Expires 2032-01-03

F1 · price: On September 24, 2026, the issuer canceled all outstanding stock options held by the reporting person pursuant to an option exchange program approved by the Compensation Committee of the issuer's Board of Directors. In exchange for the canceled options, the reporting person received a restricted stock award of an aggregate of 349,497 shares, which fully vested upon grant, valued at $4.75 per share (the closing price on September 22, 2026), equal to the aggregate Black-Scholes value of the canceled options. The option cancellation and restricted stock grant were each approved in advance by a committee of non-employee directors.

F8 · derivative.exercise_date: The canceled option provided for vesting in 4 equal installments as follows: 26,750 shall vest on each of January 1, 2023, January 1, 2024, January 1, 2025 and January 1, 2026.

Read SEC document
September 24, 2026 Filed Sep 25, 2026 20:31 UTC
KIDRON NADAVDirector · President and CEO
Disposition to issuerStock option (right to buy) · Derivative 150,000 Not disclosed Strike: $10.40 Not disclosed
Disclosure

SEC source: 0001213900-26-103540 · ownership.xml · derivative · entry 8

KIDRON NADAV · CIK 0001351779 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 150,000 shares

Expires 2031-02-03

F1 · price: On September 24, 2026, the issuer canceled all outstanding stock options held by the reporting person pursuant to an option exchange program approved by the Compensation Committee of the issuer's Board of Directors. In exchange for the canceled options, the reporting person received a restricted stock award of an aggregate of 349,497 shares, which fully vested upon grant, valued at $4.75 per share (the closing price on September 22, 2026), equal to the aggregate Black-Scholes value of the canceled options. The option cancellation and restricted stock grant were each approved in advance by a committee of non-employee directors.

F7 · derivative.exercise_date: The canceled option provided for vesting in 4 equal installments as follows: 37,500 shall vest on each of December 31, 2021, December 31, 2022, December 31, 2023 and December 31, 2024.

Read SEC document
September 24, 2026 Filed Sep 25, 2026 20:31 UTC
KIDRON NADAVDirector · President and CEO
Disposition to issuerStock option (right to buy) · Derivative 97,000 Not disclosed Strike: $8.14 Not disclosed
Disclosure

SEC source: 0001213900-26-103540 · ownership.xml · derivative · entry 7

KIDRON NADAV · CIK 0001351779 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 97,000 shares

Expires 2028-01-31

F1 · price: On September 24, 2026, the issuer canceled all outstanding stock options held by the reporting person pursuant to an option exchange program approved by the Compensation Committee of the issuer's Board of Directors. In exchange for the canceled options, the reporting person received a restricted stock award of an aggregate of 349,497 shares, which fully vested upon grant, valued at $4.75 per share (the closing price on September 22, 2026), equal to the aggregate Black-Scholes value of the canceled options. The option cancellation and restricted stock grant were each approved in advance by a committee of non-employee directors.

F6 · derivative.exercise_date: The canceled option provided for vesting in 4 equal installments of 24,250 on each of January 1, 2019, January 1, 2020, January 1, 2021 and January 1, 2022.

Read SEC document
September 24, 2026 Filed Sep 25, 2026 20:31 UTC
KIDRON NADAVDirector · President and CEO
Disposition to issuerStock option (right to buy) · Derivative 49,000 Not disclosed Strike: $7.77 Not disclosed
Disclosure

SEC source: 0001213900-26-103540 · ownership.xml · derivative · entry 6

KIDRON NADAV · CIK 0001351779 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 49,000 shares

Expires 2027-06-30

F1 · price: On September 24, 2026, the issuer canceled all outstanding stock options held by the reporting person pursuant to an option exchange program approved by the Compensation Committee of the issuer's Board of Directors. In exchange for the canceled options, the reporting person received a restricted stock award of an aggregate of 349,497 shares, which fully vested upon grant, valued at $4.75 per share (the closing price on September 22, 2026), equal to the aggregate Black-Scholes value of the canceled options. The option cancellation and restricted stock grant were each approved in advance by a committee of non-employee directors.

F5 · derivative.exercise_date: The canceled option provided for vesting in 3 equal installments of 49,000 on each of December 31, 2017, December 31, 2018 and December 31, 2019, subject to the issuer's share price reaching $8.00, $9.50 and $12.50 per share, respectively. Only the first share price target was achieved, and accordingly only 49,000 of the options vested.

Read SEC document
September 24, 2026 Filed Sep 25, 2026 20:31 UTC
KIDRON NADAVDirector · President and CEO
Disposition to issuerStock option (right to buy) · Derivative 190,000 Not disclosed Strike: $4.80 Not disclosed
Disclosure

SEC source: 0001213900-26-103540 · ownership.xml · derivative · entry 5

KIDRON NADAV · CIK 0001351779 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 190,000 shares

Expires 2030-01-08

F1 · price: On September 24, 2026, the issuer canceled all outstanding stock options held by the reporting person pursuant to an option exchange program approved by the Compensation Committee of the issuer's Board of Directors. In exchange for the canceled options, the reporting person received a restricted stock award of an aggregate of 349,497 shares, which fully vested upon grant, valued at $4.75 per share (the closing price on September 22, 2026), equal to the aggregate Black-Scholes value of the canceled options. The option cancellation and restricted stock grant were each approved in advance by a committee of non-employee directors.

F4 · derivative.exercise_date: The canceled option provided for vesting in 4 equal installments as follows: 47,500 shall vest on each of December 31, 2020, December 31, 2021, December 31, 2022 and December 31, 2023.

Read SEC document
September 24, 2026 Filed Sep 25, 2026 20:31 UTC
KIDRON NADAVDirector · President and CEO
Disposition to issuerStock option (right to buy) · Derivative 196,500 Not disclosed Strike: $3.16 Not disclosed
Disclosure

SEC source: 0001213900-26-103540 · ownership.xml · derivative · entry 4

KIDRON NADAV · CIK 0001351779 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 196,500 shares

Expires 2029-09-11

F1 · price: On September 24, 2026, the issuer canceled all outstanding stock options held by the reporting person pursuant to an option exchange program approved by the Compensation Committee of the issuer's Board of Directors. In exchange for the canceled options, the reporting person received a restricted stock award of an aggregate of 349,497 shares, which fully vested upon grant, valued at $4.75 per share (the closing price on September 22, 2026), equal to the aggregate Black-Scholes value of the canceled options. The option cancellation and restricted stock grant were each approved in advance by a committee of non-employee directors.

F3 · derivative.exercise_date: The canceled option provided for vesting in 4 equal installments of 49,125 on each of December 31, 2019, December 31, 2020, December 31, 2021 and December 31, 2022.

Read SEC document
September 24, 2026 Filed Sep 25, 2026 20:31 UTC
KIDRON NADAVDirector · President and CEO
GrantCommon Stock 368,765 Not disclosed Not disclosed
Disclosure

SEC source: 0001213900-26-103540 · ownership.xml · nonDerivative · entry 2

KIDRON NADAV · CIK 0001351779 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,140,505

F2 · price: On September 24, 2026, the issuer granted to the reporting person a restricted stock award of an aggregate of 368,765 shares pursuant to the issuer's Amended and Restated 2019 Stock Incentive Plan (the "Plan"). The restricted stock vests as to forty percent (40%) on the date of grant and as to the remaining sixty percent (60%) in eight (8) substantially equal quarterly installments over the twenty-four (24) month period following the date of grant, subject to the reporting person's continued service with the issuer. Unvested shares are subject to forfeiture in accordance with the terms of the applicable award agreement and the Plan.

Read SEC document
September 24, 2026 Filed Sep 25, 2026 20:31 UTC
KIDRON NADAVDirector · President and CEO
GrantCommon Stock 349,497 Not disclosed Not disclosed
Disclosure

SEC source: 0001213900-26-103540 · ownership.xml · nonDerivative · entry 1

KIDRON NADAV · CIK 0001351779 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,771,740

F1 · price: On September 24, 2026, the issuer canceled all outstanding stock options held by the reporting person pursuant to an option exchange program approved by the Compensation Committee of the issuer's Board of Directors. In exchange for the canceled options, the reporting person received a restricted stock award of an aggregate of 349,497 shares, which fully vested upon grant, valued at $4.75 per share (the closing price on September 22, 2026), equal to the aggregate Black-Scholes value of the canceled options. The option cancellation and restricted stock grant were each approved in advance by a committee of non-employee directors.

Read SEC document
September 24, 2026 Filed Sep 25, 2026 20:30 UTC
Kidron MiriamDirector · Chief Scientific Officer
Disposition to issuerStock option (right to buy) · Derivative 72,000 Not disclosed Strike: $13.89 Not disclosed
Disclosure

SEC source: 0001213900-26-103536 · ownership.xml · derivative · entry 8

Kidron Miriam · CIK 0001409232 · Director · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 72,000 shares

Expires 2032-01-03

F1 · price: On September 24, 2026, the issuer canceled all outstanding stock options held by the reporting person pursuant to an option exchange program approved by the Compensation Committee of the issuer's Board of Directors. In exchange for the canceled options, the reporting person received a restricted stock award of an aggregate of 208,125 shares, which fully vested upon grant, valued at $4.75 per share (the closing price on September 22, 2026), equal to the aggregate Black-Scholes value of the canceled options. The option cancellation and restricted stock grant were each approved in advance by a committee of non-employee directors.

F8 · derivative.exercise_date: The canceled option provided for vesting in 4 equal installments as follows: 18,000 shall vest on each of January 1, 2023, January 1, 2024, January 1, 2025 and January 1, 2026.

Read SEC document
September 24, 2026 Filed Sep 25, 2026 20:30 UTC
Kidron MiriamDirector · Chief Scientific Officer
Disposition to issuerStock option (right to buy) · Derivative 100,000 Not disclosed Strike: $10.40 Not disclosed
Disclosure

SEC source: 0001213900-26-103536 · ownership.xml · derivative · entry 7

Kidron Miriam · CIK 0001409232 · Director · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 100,000 shares

Expires 2031-02-03

F1 · price: On September 24, 2026, the issuer canceled all outstanding stock options held by the reporting person pursuant to an option exchange program approved by the Compensation Committee of the issuer's Board of Directors. In exchange for the canceled options, the reporting person received a restricted stock award of an aggregate of 208,125 shares, which fully vested upon grant, valued at $4.75 per share (the closing price on September 22, 2026), equal to the aggregate Black-Scholes value of the canceled options. The option cancellation and restricted stock grant were each approved in advance by a committee of non-employee directors.

F7 · derivative.exercise_date: The canceled option provided for vesting in 4 equal installments as follows: 25,000 shall vest on each of December 31, 2021, December 31, 2022, December 31, 2023 and December 31, 2024.

Read SEC document
September 24, 2026 Filed Sep 25, 2026 20:30 UTC
Kidron MiriamDirector · Chief Scientific Officer
Disposition to issuerStock option (right to buy) · Derivative 47,000 Not disclosed Strike: $8.14 Not disclosed
Disclosure

SEC source: 0001213900-26-103536 · ownership.xml · derivative · entry 6

Kidron Miriam · CIK 0001409232 · Director · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 47,000 shares

Expires 2028-01-31

F1 · price: On September 24, 2026, the issuer canceled all outstanding stock options held by the reporting person pursuant to an option exchange program approved by the Compensation Committee of the issuer's Board of Directors. In exchange for the canceled options, the reporting person received a restricted stock award of an aggregate of 208,125 shares, which fully vested upon grant, valued at $4.75 per share (the closing price on September 22, 2026), equal to the aggregate Black-Scholes value of the canceled options. The option cancellation and restricted stock grant were each approved in advance by a committee of non-employee directors.

F6 · derivative.exercise_date: The canceled option provided for vesting in 4 equal installments of 11,750 on each of January 1, 2019, January 1, 2020, January 1, 2021 and January 1, 2022.

Read SEC document
September 24, 2026 Filed Sep 25, 2026 20:30 UTC
Kidron MiriamDirector · Chief Scientific Officer
Disposition to issuerStock option (right to buy) · Derivative 69,999 Not disclosed Strike: $7.77 Not disclosed
Disclosure

SEC source: 0001213900-26-103536 · ownership.xml · derivative · entry 5

Kidron Miriam · CIK 0001409232 · Director · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 69,999 shares

Expires 2027-06-30

F1 · price: On September 24, 2026, the issuer canceled all outstanding stock options held by the reporting person pursuant to an option exchange program approved by the Compensation Committee of the issuer's Board of Directors. In exchange for the canceled options, the reporting person received a restricted stock award of an aggregate of 208,125 shares, which fully vested upon grant, valued at $4.75 per share (the closing price on September 22, 2026), equal to the aggregate Black-Scholes value of the canceled options. The option cancellation and restricted stock grant were each approved in advance by a committee of non-employee directors.

F5 · derivative.exercise_date: The canceled option provided for vesting in 3 equal installments of 23,333 on each of December 31, 2017, December 31, 2018 and December 31, 2019.

Read SEC document
September 24, 2026 Filed Sep 25, 2026 20:30 UTC
Kidron MiriamDirector · Chief Scientific Officer
Disposition to issuerStock option (right to buy) · Derivative 100,000 Not disclosed Strike: $4.80 Not disclosed
Disclosure

SEC source: 0001213900-26-103536 · ownership.xml · derivative · entry 4

Kidron Miriam · CIK 0001409232 · Director · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 100,000 shares

Expires 2030-01-08

F1 · price: On September 24, 2026, the issuer canceled all outstanding stock options held by the reporting person pursuant to an option exchange program approved by the Compensation Committee of the issuer's Board of Directors. In exchange for the canceled options, the reporting person received a restricted stock award of an aggregate of 208,125 shares, which fully vested upon grant, valued at $4.75 per share (the closing price on September 22, 2026), equal to the aggregate Black-Scholes value of the canceled options. The option cancellation and restricted stock grant were each approved in advance by a committee of non-employee directors.

F4 · derivative.exercise_date: The canceled option provided for vesting in 4 equal installments as follows: 25,000 shall vest on each of December 31, 2020, December 31, 2021, December 31, 2022 and December 31, 2023.

Read SEC document
September 24, 2026 Filed Sep 25, 2026 20:30 UTC
Kidron MiriamDirector · Chief Scientific Officer
Disposition to issuerStock option (right to buy) · Derivative 104,000 Not disclosed Strike: $3.16 Not disclosed
Disclosure

SEC source: 0001213900-26-103536 · ownership.xml · derivative · entry 3

Kidron Miriam · CIK 0001409232 · Director · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 104,000 shares

Expires 2029-09-11

F1 · price: On September 24, 2026, the issuer canceled all outstanding stock options held by the reporting person pursuant to an option exchange program approved by the Compensation Committee of the issuer's Board of Directors. In exchange for the canceled options, the reporting person received a restricted stock award of an aggregate of 208,125 shares, which fully vested upon grant, valued at $4.75 per share (the closing price on September 22, 2026), equal to the aggregate Black-Scholes value of the canceled options. The option cancellation and restricted stock grant were each approved in advance by a committee of non-employee directors.

F3 · derivative.exercise_date: The canceled option provided for vesting in 4 equal installments of 26,000 on each of December 31, 2019, December 31, 2020, December 31, 2021 and December 31, 2022.

Read SEC document
September 24, 2026 Filed Sep 25, 2026 20:30 UTC
Kidron MiriamDirector · Chief Scientific Officer
GrantCommon Stock 209,291 Not disclosed Not disclosed
Disclosure

SEC source: 0001213900-26-103536 · ownership.xml · nonDerivative · entry 2

Kidron Miriam · CIK 0001409232 · Director · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,550,554

F2 · price: On September 24, 2026, the issuer granted to the reporting person a restricted stock award of an aggregate of 209,291 shares pursuant to the issuer's Amended and Restated 2019 Stock Incentive Plan (the "Plan"). The restricted stock vests as to forty percent (40%) on the date of grant and as to the remaining sixty percent (60%) in eight (8) substantially equal quarterly installments over the twenty-four (24) month period following the date of grant, subject to the reporting person's continued service with the issuer. Unvested shares are subject to forfeiture in accordance with the terms of the applicable award agreement and the Plan.

Read SEC document
September 24, 2026 Filed Sep 25, 2026 20:30 UTC
Kidron MiriamDirector · Chief Scientific Officer
GrantCommon Stock 208,125 Not disclosed Not disclosed
Disclosure

SEC source: 0001213900-26-103536 · ownership.xml · nonDerivative · entry 1

Kidron Miriam · CIK 0001409232 · Director · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,341,263

F1 · price: On September 24, 2026, the issuer canceled all outstanding stock options held by the reporting person pursuant to an option exchange program approved by the Compensation Committee of the issuer's Board of Directors. In exchange for the canceled options, the reporting person received a restricted stock award of an aggregate of 208,125 shares, which fully vested upon grant, valued at $4.75 per share (the closing price on September 22, 2026), equal to the aggregate Black-Scholes value of the canceled options. The option cancellation and restricted stock grant were each approved in advance by a committee of non-employee directors.

Read SEC document
September 24, 2026 Filed Sep 25, 2026 20:30 UTC
Gabay AvrahamChief Financial Officer
GrantCommon Stock 209,291 Not disclosed Not disclosed
Disclosure

SEC source: 0001213900-26-103535 · ownership.xml · nonDerivative · entry 1

Gabay Avraham · CIK 0001777328 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 881,076

F1 · price: On September 24, 2026, the issuer granted to the reporting person a restricted stock award of an aggregate of 209,291 shares pursuant to the issuer's Amended and Restated 2019 Stock Incentive Plan (the "Plan"). The restricted stock vests as to forty percent (40%) on the date of grant and as to the remaining sixty percent (60%) in eight (8) substantially equal quarterly installments over the twenty-four (24) month period following the date of grant, subject to the reporting person's continued service with the issuer. Unvested shares are subject to forfeiture in accordance with the terms of the applicable award agreement and the Plan.

Read SEC document
September 24, 2026 Filed Sep 25, 2026 20:31 UTC
Hexter JoshuaCOO & CBO
Disposition to issuerStock option (right to buy) · Derivative 36,000 Not disclosed Strike: $13.89 Not disclosed
Disclosure

SEC source: 0001213900-26-103538 · ownership.xml · derivative · entry 5

Hexter Joshua · CIK 0001573235 · COO & CBO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 36,000 shares

Expires 2032-01-03

F1 · price: On September 24, 2026, the issuer canceled all outstanding stock options held by the reporting person pursuant to an option exchange program approved by the Compensation Committee of the issuer's Board of Directors. In exchange for the canceled options, the reporting person received a restricted stock award of an aggregate of 75,455 shares, which fully vested upon grant, valued at $4.75 per share (the closing price on September 22, 2026), equal to the aggregate Black-Scholes value of the canceled options. The option cancellation and restricted stock grant were each approved in advance by a committee of non-employee directors.

F5 · derivative.exercise_date: The canceled option provided for vesting in 4 equal installments as follows: 9,000 shall vest on each of January 1, 2023, January 1, 2024, January 1, 2025 and January 1, 2026.

Read SEC document
September 24, 2026 Filed Sep 25, 2026 20:31 UTC
Hexter JoshuaCOO & CBO
Disposition to issuerStock option (right to buy) · Derivative 50,000 Not disclosed Strike: $10.40 Not disclosed
Disclosure

SEC source: 0001213900-26-103538 · ownership.xml · derivative · entry 4

Hexter Joshua · CIK 0001573235 · COO & CBO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 50,000 shares

Expires 2031-02-03

F1 · price: On September 24, 2026, the issuer canceled all outstanding stock options held by the reporting person pursuant to an option exchange program approved by the Compensation Committee of the issuer's Board of Directors. In exchange for the canceled options, the reporting person received a restricted stock award of an aggregate of 75,455 shares, which fully vested upon grant, valued at $4.75 per share (the closing price on September 22, 2026), equal to the aggregate Black-Scholes value of the canceled options. The option cancellation and restricted stock grant were each approved in advance by a committee of non-employee directors.

F4 · derivative.exercise_date: The canceled option provided for vesting in 4 equal installments as follows: 12,500 shall vest on each of December 31, 2021, December 31, 2022, December 31, 2023 and December 31, 2024.

Read SEC document
September 24, 2026 Filed Sep 25, 2026 20:31 UTC
Hexter JoshuaCOO & CBO
Disposition to issuerStock option (right to buy) · Derivative 50,000 Not disclosed Strike: $3.69 Not disclosed
Disclosure

SEC source: 0001213900-26-103538 · ownership.xml · derivative · entry 3

Hexter Joshua · CIK 0001573235 · COO & CBO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 50,000 shares

Expires 2029-09-11

F1 · price: On September 24, 2026, the issuer canceled all outstanding stock options held by the reporting person pursuant to an option exchange program approved by the Compensation Committee of the issuer's Board of Directors. In exchange for the canceled options, the reporting person received a restricted stock award of an aggregate of 75,455 shares, which fully vested upon grant, valued at $4.75 per share (the closing price on September 22, 2026), equal to the aggregate Black-Scholes value of the canceled options. The option cancellation and restricted stock grant were each approved in advance by a committee of non-employee directors.

F3 · derivative.exercise_date: The canceled option provided for vesting in 16 equal installments of 6,250 on the first day of every three-month period beginning November 1, 2019. Of the vested options, 50,000 were previously exercised.

Read SEC document
September 24, 2026 Filed Sep 25, 2026 20:31 UTC
Hexter JoshuaCOO & CBO
GrantCommon Stock 209,291 Not disclosed Not disclosed
Disclosure

SEC source: 0001213900-26-103538 · ownership.xml · nonDerivative · entry 2

Hexter Joshua · CIK 0001573235 · COO & CBO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,358,130

F2 · price: On September 24, 2026, the issuer granted to the reporting person a restricted stock award of an aggregate of 209,291 shares pursuant to the issuer's Amended and Restated 2019 Stock Incentive Plan (the "Plan"). The restricted stock vests as to forty percent (40%) on the date of grant and as to the remaining sixty percent (60%) in eight (8) substantially equal quarterly installments over the twenty-four (24) month period following the date of grant, subject to the reporting person's continued service with the issuer. Unvested shares are subject to forfeiture in accordance with the terms of the applicable award agreement and the Plan.

Read SEC document
September 24, 2026 Filed Sep 25, 2026 20:31 UTC
Hexter JoshuaCOO & CBO
GrantCommon Stock 75,455 Not disclosed Not disclosed
Disclosure

SEC source: 0001213900-26-103538 · ownership.xml · nonDerivative · entry 1

Hexter Joshua · CIK 0001573235 · COO & CBO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,148,839

F1 · price: On September 24, 2026, the issuer canceled all outstanding stock options held by the reporting person pursuant to an option exchange program approved by the Compensation Committee of the issuer's Board of Directors. In exchange for the canceled options, the reporting person received a restricted stock award of an aggregate of 75,455 shares, which fully vested upon grant, valued at $4.75 per share (the closing price on September 22, 2026), equal to the aggregate Black-Scholes value of the canceled options. The option cancellation and restricted stock grant were each approved in advance by a committee of non-employee directors.

Read SEC document
July 02, 2026 Filed Jul 2, 2026 21:00 UTC
Hexter JoshuaCOO & CBO
Exercise / conversionStock option (right to buy) · Derivative 50,000 $0.00 Strike: $3.69 $0.00
Disclosure

SEC source: 0001213900-26-075070 · ownership.xml · derivative · entry 3

Hexter Joshua · CIK 0001573235 · COO & CBO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2029-09-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The stock options vested and became exercisable in 16 equal installments of 6,250 on the first day of every three-month period beginning November 1, 2019.

Read SEC document
July 02, 2026 Filed Jul 2, 2026 21:00 UTC
Hexter JoshuaCOO & CBO
Exercise / conversionCommon Stock 50,000 $3.69 $184,500.00
Disclosure

SEC source: 0001213900-26-075070 · ownership.xml · nonDerivative · entry 2

Hexter Joshua · CIK 0001573235 · COO & CBO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,073,384

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
July 01, 2026 Filed Jul 2, 2026 21:00 UTC
Hexter JoshuaCOO & CBO
SaleCommon Stock 137,000 $4.46 $611,431.00
Disclosure

SEC source: 0001213900-26-075070 · ownership.xml · nonDerivative · entry 1

Hexter Joshua · CIK 0001573235 · COO & CBO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,023,384

F1 · shares: Represents shares sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 30, 2026.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.255 to $4.7652, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Read SEC document
July 01, 2026 Filed Jul 2, 2026 21:00 UTC
Gabay AvrahamChief Financial Officer
SaleCommon Stock 73,360 $4.51 $330,743.56
Disclosure

SEC source: 0001213900-26-075069 · ownership.xml · nonDerivative · entry 1

Gabay Avraham · CIK 0001777328 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 671,785

F1 · shares: Represents shares sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 30, 2026.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.255 to $4.750, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Read SEC document
March 30, 2026 Filed Mar 31, 2026 20:10 UTC
KIDRON NADAVDirector · President and CEO
Tax withholdingCommon Stock 44,818 $3.31 $148,347.58
Disclosure

SEC source: 0001213900-26-037447 · ownership.xml · nonDerivative · entry 1

KIDRON NADAV · CIK 0001351779 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,422,243

F1 · shares: Represents shares of common stock, par value $0.012 per share ("Common Stock"), of the Issuer used to satisfy tax withholding obligations attributable to the vesting and settlement of Restricted Stock Units, which were valued at the closing price of the Issuer's Common Stock on the date immediately prior to the vesting date, equal to $3.31 per share.

F1 · price: Represents shares of common stock, par value $0.012 per share ("Common Stock"), of the Issuer used to satisfy tax withholding obligations attributable to the vesting and settlement of Restricted Stock Units, which were valued at the closing price of the Issuer's Common Stock on the date immediately prior to the vesting date, equal to $3.31 per share.

Read SEC document
March 30, 2026 Filed Mar 31, 2026 20:10 UTC
Kidron MiriamDirector · Chief Scientific Officer
Tax withholdingCommon Stock 435,084 $3.31 $1,440,128.04
Disclosure

SEC source: 0001213900-26-037446 · ownership.xml · nonDerivative · entry 1

Kidron Miriam · CIK 0001409232 · Director · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,133,138

F1 · shares: Represents shares of common stock, par value $0.012 per share ("Common Stock"), of the Issuer used to satisfy tax withholding obligations attributable to the vesting and settlement of Restricted Stock Units, which were valued at the closing price of the Issuer's Common Stock on the date immediately prior to the vesting date, equal to $3.31 per share.

F1 · price: Represents shares of common stock, par value $0.012 per share ("Common Stock"), of the Issuer used to satisfy tax withholding obligations attributable to the vesting and settlement of Restricted Stock Units, which were valued at the closing price of the Issuer's Common Stock on the date immediately prior to the vesting date, equal to $3.31 per share.

Read SEC document
March 17, 2026 Filed Mar 18, 2026 21:46 UTC
Kidron MiriamDirector · Chief Scientific Officer
GrantCommon Stock 119,558 $0.00 $0.00
Disclosure

SEC source: 0001213900-26-031015 · ownership.xml · nonDerivative · entry 1

Kidron Miriam · CIK 0001409232 · Director · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,568,222

F1 · shares: Represents Restricted Stock Units ("RSUs"). The RSUs will vest ratably in 8 quarterly installments beginning April 1, 2026. Each RSU represents the right to receive one share of common stock, par value $0.012 per share, of the Issuer.

F1 · price: Represents Restricted Stock Units ("RSUs"). The RSUs will vest ratably in 8 quarterly installments beginning April 1, 2026. Each RSU represents the right to receive one share of common stock, par value $0.012 per share, of the Issuer.

Read SEC document
March 17, 2026 Filed Mar 18, 2026 21:46 UTC
KIDRON NADAVDirector · President and CEO
GrantCommon Stock 167,005 $0.00 $0.00
Disclosure

SEC source: 0001213900-26-031013 · ownership.xml · nonDerivative · entry 1

KIDRON NADAV · CIK 0001351779 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,422,243

F1 · shares: Represents Restricted Stock Units ("RSUs"). The RSUs will vest ratably in 8 quarterly installments beginning April 1, 2026. Each RSU represents the right to receive one share of common stock, par value $0.012 per share, of the Issuer.

F1 · price: Represents Restricted Stock Units ("RSUs"). The RSUs will vest ratably in 8 quarterly installments beginning April 1, 2026. Each RSU represents the right to receive one share of common stock, par value $0.012 per share, of the Issuer.

Read SEC document
March 17, 2026 Filed Mar 18, 2026 21:46 UTC
Hexter JoshuaCOO & CBO
GrantCommon Stock 95,889 $0.00 $0.00
Disclosure

SEC source: 0001213900-26-031012 · ownership.xml · nonDerivative · entry 1

Hexter Joshua · CIK 0001573235 · COO & CBO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,160,384

F1 · shares: Represents Restricted Stock Units ("RSUs"). The RSUs will vest ratably in 8 quarterly installments beginning April 1, 2026. Each RSU represents the right to receive one share of common stock, par value $0.012 per share, of the Issuer.

F1 · price: Represents Restricted Stock Units ("RSUs"). The RSUs will vest ratably in 8 quarterly installments beginning April 1, 2026. Each RSU represents the right to receive one share of common stock, par value $0.012 per share, of the Issuer.

Read SEC document
March 17, 2026 Filed Mar 18, 2026 21:45 UTC
Gabay AvrahamChief Financial Officer
GrantCommon Stock 95,889 $0.00 $0.00
Disclosure

SEC source: 0001213900-26-031011 · ownership.xml · nonDerivative · entry 1

Gabay Avraham · CIK 0001777328 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 745,145

F1 · shares: Represents Restricted Stock Units ("RSUs"). The RSUs will vest ratably in 8 quarterly installments beginning April 1, 2026. Each RSU represents the right to receive one share of common stock, par value $0.012 per share, of the Issuer.

F1 · price: Represents Restricted Stock Units ("RSUs"). The RSUs will vest ratably in 8 quarterly installments beginning April 1, 2026. Each RSU represents the right to receive one share of common stock, par value $0.012 per share, of the Issuer.

Read SEC document
March 12, 2026 Filed Mar 16, 2026 20:06 UTC
KIDRON NADAVDirector · President and CEO
GiftCommon Stock 100,000 $0.00 $0.00
Disclosure

SEC source: 0001213900-26-028291 · ownership.xml · nonDerivative · entry 1

KIDRON NADAV · CIK 0001351779 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,255,238

F1 · kind: This transaction represents a charitable donation and is not a market transaction, thus no price has been reported. No value was received for the donated shares. The Reporting Person is not affiliated with, and has no control over, the donee.

Read SEC document
January 22, 2026 Filed Jan 29, 2026 21:05 UTC
Hexter JoshuaCOO & CBO
Exercise / conversionPerformance Stock Units · Derivative 19,000 $0.00 $0.00
Disclosure

SEC source: 0001213900-26-009477 · ownership.xml · derivative · entry 2

Hexter Joshua · CIK 0001573235 · COO & CBO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 19,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Represents the vesting of performance stock units ("PSUs") granted to the Reporting Person on December 31, 2025, which vested on January 22, 2026, upon the Issuer's common stock, par value $0.012 per share ("Common Stock"), achieving a specified price per share. The shares of Common Stock were received for no consideration upon such vesting.

F2 · derivative.exercise_date: Each PSU represented a contingent right to receive one share of the Issuer's Common Stock upon achievement of the applicable performance criteria.

F2 · derivative.expiration_date: Each PSU represented a contingent right to receive one share of the Issuer's Common Stock upon achievement of the applicable performance criteria.

Read SEC document
January 22, 2026 Filed Jan 29, 2026 21:05 UTC
Hexter JoshuaCOO & CBO
Exercise / conversionCommon Stock 19,000 $0.00 $0.00
Disclosure

SEC source: 0001213900-26-009477 · ownership.xml · nonDerivative · entry 1

Hexter Joshua · CIK 0001573235 · COO & CBO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,064,495

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents the vesting of performance stock units ("PSUs") granted to the Reporting Person on December 31, 2025, which vested on January 22, 2026, upon the Issuer's common stock, par value $0.012 per share ("Common Stock"), achieving a specified price per share. The shares of Common Stock were received for no consideration upon such vesting.

F1 · price: Represents the vesting of performance stock units ("PSUs") granted to the Reporting Person on December 31, 2025, which vested on January 22, 2026, upon the Issuer's common stock, par value $0.012 per share ("Common Stock"), achieving a specified price per share. The shares of Common Stock were received for no consideration upon such vesting.

Read SEC document
January 22, 2026 Filed Jan 29, 2026 21:05 UTC
Kidron MiriamDirector · Chief Scientific Officer
Exercise / conversionPerformance Stock Units · Derivative 19,000 $0.00 $0.00
Disclosure

SEC source: 0001213900-26-009478 · ownership.xml · derivative · entry 2

Kidron Miriam · CIK 0001409232 · Director · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 19,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Represents the vesting of performance stock units ("PSUs") granted to the Reporting Person on December 31, 2025, which vested on January 22, 2026, upon the Issuer's common stock, par value $0.012 per share ("Common Stock"), achieving a specified price per share. The shares of Common Stock were received for no consideration upon such vesting.

F2 · derivative.exercise_date: Each PSU represented a contingent right to receive one share of the Issuer's Common Stock upon achievement of the applicable performance criteria.

F2 · derivative.expiration_date: Each PSU represented a contingent right to receive one share of the Issuer's Common Stock upon achievement of the applicable performance criteria.

Read SEC document
January 22, 2026 Filed Jan 29, 2026 21:05 UTC
Kidron MiriamDirector · Chief Scientific Officer
Exercise / conversionCommon Stock 19,000 $0.00 $0.00
Disclosure

SEC source: 0001213900-26-009478 · ownership.xml · nonDerivative · entry 1

Kidron Miriam · CIK 0001409232 · Director · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,448,664

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents the vesting of performance stock units ("PSUs") granted to the Reporting Person on December 31, 2025, which vested on January 22, 2026, upon the Issuer's common stock, par value $0.012 per share ("Common Stock"), achieving a specified price per share. The shares of Common Stock were received for no consideration upon such vesting.

F1 · price: Represents the vesting of performance stock units ("PSUs") granted to the Reporting Person on December 31, 2025, which vested on January 22, 2026, upon the Issuer's common stock, par value $0.012 per share ("Common Stock"), achieving a specified price per share. The shares of Common Stock were received for no consideration upon such vesting.

Read SEC document
January 22, 2026 Filed Jan 29, 2026 21:05 UTC
Gabay AvrahamChief Financial Officer
Exercise / conversionPerformance Stock Units · Derivative 19,000 $0.00 $0.00
Disclosure

SEC source: 0001213900-26-009476 · ownership.xml · derivative · entry 2

Gabay Avraham · CIK 0001777328 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 19,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Represents the vesting of performance stock units ("PSUs") granted to the Reporting Person on December 31, 2025, which vested on January 22, 2026, upon the Issuer's common stock, par value $0.012 per share ("Common Stock"), achieving a specified price per share. The shares of Common Stock were received for no consideration upon such vesting.

F2 · derivative.exercise_date: Each PSU represented a contingent right to receive one share of the Issuer's Common Stock upon achievement of the applicable performance criteria.

F2 · derivative.expiration_date: Each PSU represented a contingent right to receive one share of the Issuer's Common Stock upon achievement of the applicable performance criteria.

Read SEC document
January 22, 2026 Filed Jan 29, 2026 21:05 UTC
Gabay AvrahamChief Financial Officer
Exercise / conversionCommon Stock 19,000 $0.00 $0.00
Disclosure

SEC source: 0001213900-26-009476 · ownership.xml · nonDerivative · entry 1

Gabay Avraham · CIK 0001777328 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 649,256

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents the vesting of performance stock units ("PSUs") granted to the Reporting Person on December 31, 2025, which vested on January 22, 2026, upon the Issuer's common stock, par value $0.012 per share ("Common Stock"), achieving a specified price per share. The shares of Common Stock were received for no consideration upon such vesting.

F1 · price: Represents the vesting of performance stock units ("PSUs") granted to the Reporting Person on December 31, 2025, which vested on January 22, 2026, upon the Issuer's common stock, par value $0.012 per share ("Common Stock"), achieving a specified price per share. The shares of Common Stock were received for no consideration upon such vesting.

Read SEC document
January 22, 2026 Filed Jan 29, 2026 21:05 UTC
KIDRON NADAVDirector · President and CEO
Exercise / conversionPerformance Stock Units · Derivative 109,000 $0.00 $0.00
Disclosure

SEC source: 0001213900-26-009479 · ownership.xml · derivative · entry 2

KIDRON NADAV · CIK 0001351779 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 109,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Represents the vesting of performance stock units ("PSUs") granted to the Reporting Person on December 31, 2025, which vested on January 22, 2026, upon the Issuer's common stock, par value $0.012 per share ("Common Stock"), achieving a specified price per share. The shares of Common Stock were received for no consideration upon such vesting.

F2 · derivative.exercise_date: Each PSU represented a contingent right to receive one share of the Issuer's Common Stock upon achievement of the applicable performance criteria.

F2 · derivative.expiration_date: Each PSU represented a contingent right to receive one share of the Issuer's Common Stock upon achievement of the applicable performance criteria.

Read SEC document
January 22, 2026 Filed Jan 29, 2026 21:05 UTC
KIDRON NADAVDirector · President and CEO
Exercise / conversionCommon Stock 109,000 $0.00 $0.00
Disclosure

SEC source: 0001213900-26-009479 · ownership.xml · nonDerivative · entry 1

KIDRON NADAV · CIK 0001351779 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,355,238

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents the vesting of performance stock units ("PSUs") granted to the Reporting Person on December 31, 2025, which vested on January 22, 2026, upon the Issuer's common stock, par value $0.012 per share ("Common Stock"), achieving a specified price per share. The shares of Common Stock were received for no consideration upon such vesting.

F1 · price: Represents the vesting of performance stock units ("PSUs") granted to the Reporting Person on December 31, 2025, which vested on January 22, 2026, upon the Issuer's common stock, par value $0.012 per share ("Common Stock"), achieving a specified price per share. The shares of Common Stock were received for no consideration upon such vesting.

Read SEC document
January 14, 2026 Filed Jan 21, 2026 21:30 UTC
Kidron MiriamDirector · Chief Scientific Officer
GiftCommon Stock 86,166 $0.00 $0.00
Disclosure

SEC source: 0001213900-26-006215 · ownership.xml · nonDerivative · entry 1

Kidron Miriam · CIK 0001409232 · Director · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,343,498

F1 · kind: This transaction represents a charitable donation and is not a market transaction, thus no price has been reported. No value was received for the donated shares. The Reporting Person is not affiliated with, and has no control over, the donee.

Read SEC document
December 31, 2025 Filed Jan 3, 2026 01:02 UTC GrantCommon Stock 6,250 Not disclosed Not disclosed
Disclosure

SEC source: 0001213900-26-000661 · ownership.xml · nonDerivative · entry 2

Aghion Daniel · CIK 0002004805 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 113,441

F2 · shares: Represents RSUs. The RSUs will vest in quarterly installments over a one-year period starting April 1, 2026. Each RSU represents the right to receive one share of Common Stock of the Issuer.

F2 · price: Represents RSUs. The RSUs will vest in quarterly installments over a one-year period starting April 1, 2026. Each RSU represents the right to receive one share of Common Stock of the Issuer.

Read SEC document
December 31, 2025 Filed Jan 3, 2026 01:02 UTC GrantCommon Stock 30,000 Not disclosed Not disclosed
Disclosure

SEC source: 0001213900-26-000661 · ownership.xml · nonDerivative · entry 1

Aghion Daniel · CIK 0002004805 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 107,191

F1 · shares: Represents Restricted Stock Units ("RSUs"). The RSUs will vest ratably in three annual tranches beginning January 1, 2027. Each RSU represents the right to receive one share of common stock, par value $0.012 per share ("Common Stock"), of the Issuer.

F1 · price: Represents Restricted Stock Units ("RSUs"). The RSUs will vest ratably in three annual tranches beginning January 1, 2027. Each RSU represents the right to receive one share of common stock, par value $0.012 per share ("Common Stock"), of the Issuer.

Read SEC document
December 31, 2025 Filed Jan 3, 2026 01:00 UTC
Gabay AvrahamChief Financial Officer
GrantPerformance Stock Units · Derivative 19,000 $0.00 $0.00
Disclosure

SEC source: 0001213900-26-000658 · ownership.xml · derivative · entry 3

Gabay Avraham · CIK 0001777328 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,000

Underlying: Common Stock · 19,000 shares

Expires not disclosed

F3 · derivative.exercise_price: Each performance stock unit ("PSU") represents a contingent right to receive one share of the Issuer's Common Stock. The PSUs vest upon the achievement of either (i) the Issuer's Common Stock achieving a specified price per share, or (ii) the achievement of the applicable performance criteria.

F3 · derivative.exercise_date: Each performance stock unit ("PSU") represents a contingent right to receive one share of the Issuer's Common Stock. The PSUs vest upon the achievement of either (i) the Issuer's Common Stock achieving a specified price per share, or (ii) the achievement of the applicable performance criteria.

F3 · derivative.expiration_date: Each performance stock unit ("PSU") represents a contingent right to receive one share of the Issuer's Common Stock. The PSUs vest upon the achievement of either (i) the Issuer's Common Stock achieving a specified price per share, or (ii) the achievement of the applicable performance criteria.

Read SEC document
December 31, 2025 Filed Jan 3, 2026 01:00 UTC
Gabay AvrahamChief Financial Officer
GrantCommon Stock 115,000 $0.00 $0.00
Disclosure

SEC source: 0001213900-26-000658 · ownership.xml · nonDerivative · entry 2

Gabay Avraham · CIK 0001777328 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 630,256

F2 · shares: Represents RSUs that will vest in quarterly installments over a three-year period starting January 1, 2026. Each RSU represents the right to receive one share of Common Stock of the Issuer.

F2 · price: Represents RSUs that will vest in quarterly installments over a three-year period starting January 1, 2026. Each RSU represents the right to receive one share of Common Stock of the Issuer.

Read SEC document
December 31, 2025 Filed Jan 3, 2026 01:00 UTC
Gabay AvrahamChief Financial Officer
GrantCommon Stock 81,216 $0.00 $0.00
Disclosure

SEC source: 0001213900-26-000658 · ownership.xml · nonDerivative · entry 1

Gabay Avraham · CIK 0001777328 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 515,256

F1 · shares: Represents Restricted Stock Units ("RSUs") that vested in full on January 1, 2026. Each RSU represents the right to receive one share of common stock, par value $0.012 per share ("Common Stock"), of the Issuer.

F1 · price: Represents Restricted Stock Units ("RSUs") that vested in full on January 1, 2026. Each RSU represents the right to receive one share of common stock, par value $0.012 per share ("Common Stock"), of the Issuer.

Read SEC document
December 31, 2025 Filed Jan 5, 2026 22:21 UTC GrantCommon Stock 6,250 Not disclosed Not disclosed
Disclosure

SEC source: 0001213900-26-001282 · ownership.xml · nonDerivative · entry 2

Reznick Yehuda · CIK 0002015556 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 105,180

F2 · shares: Represents RSUs. The RSUs will vest in quarterly installments over a one-year period starting April 1, 2026. Each RSU represents the right to receive one share of Common Stock of the Issuer.

F2 · price: Represents RSUs. The RSUs will vest in quarterly installments over a one-year period starting April 1, 2026. Each RSU represents the right to receive one share of Common Stock of the Issuer.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.